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OBJECTIVE— This study aims to establish the benefits of lowering cholesterol in diabetic
patients with well-controlled hypertension and average/below-average cholesterol concentra-
tions, but without established coronary disease.
RESEARCH DESIGN AND METHODS— In the lipid-lowering arm of the Anglo-
Scandinavian Cardiac Outcomes Trial (ASCOT-LLA), 10,305 hypertensive patients with no
history of coronary heart disease (CHD) but at least three cardiovascular risk factors were
randomly assigned to receive 10 mg atorvastatin or placebo. Effects on total cardiovascular
outcomes in 2,532 patients who had type 2 diabetes at randomization were compared.
RESULTS— During a median follow-up of 3.3 years, concentrations of total and LDL cho-
lesterol among diabetic participants included in ASCOT-LLA were 1 mmol/l lower in those
allocated atorvastatin compared with placebo.
There were 116 (9.2%) major cardiovascular
events or procedures in the atorvastatin group
and 151 (11.9%) events in the placebo group
(hazard ratio 0.77, 95% CI 0.61–0.98; P 
0.036). For the individual components of this
composite end point, the number of events
occurring in the diabetes subgroup was small.
Therefore, although fewer coronary events
(0.84, 0.55–1.29; P 0.14) and strokes (0.67,
0.41–1.09; P  0.66) were observed among
the patients allocated atorvastatin, these re-
ductions were not statistically significant.
CONCLUSIONS — Atorvastatin signifi-
cantly reduced the risk of major cardiovascu-
lar events and procedures among diabetic
patients with well-controlled hypertension
and without a history of CHD or markedly
elevated cholesterol concentrations. The pro-
portional reduction in risk was similar to that
among participants who did not have diag-
nosed diabetes. Allocation to atorvastatin pre-
vented9 diabetic participants from suffering
a first major cardiovascular event or procedure
for every 1,000 treated for 1 year.
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D iabetes is a major cause of cardio-vascular morbidity and mortality(1), and patients with diabetes are
usually hypertensive (2). Observational
data indicate that when risk factors such
as raised blood pressure, dyslipidemia,
and diabetes coexist, they exert a multi-
plicative effect on the absolute risk of ex-
periencing cardiovascular events (3), and
for any combination of risk factors, car-
diovascular risk is higher among diabetic
than nondiabetic patients (4). Patients
with type 2 diabetes have a dyslipidemia
typically characterized by low levels of
HDL cholesterol and raised triglyceride
levels rather than elevated LDL or total
cholesterol levels (5).
Before the recruitment of patients
into the Anglo-Scandinavian Cardiac
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Outcomes Trial (ASCOT) (6), only small
numbers of diabetic patients without vas-
cular disease had been included in trials
of lipid-lowering therapy (7,8). More re-
cently, two trials incorporating substan-
tial numbers of diabetic patients have
been reported. In the Heart Protection
Study (HPS) (9), substantial benefits of
lipid lowering were demonstrated in a co-
hort of 5,963 diabetic subjects, both in
the presence (51%) and absence (49%) of
established cardiovascular disease (10).
In the Collaborative Atorvastatin Diabetes
Study (CARDS), 2,838 subjects with type
2 diabetes who did not have established
cardiovascular disease were randomly as-
signed to receive atorvastatin or placebo
(11). In CARDS, statin treatment signifi-
cantly reduced the composite primary
end point of major cardiovascular events
by 37%.
The relative risk reduction in end
points associated with statin use appears in-
dependent of the baseline cholesterol con-
centration (7,12). Hence it is important to
evaluate the impact of statin use in patients
at relatively high absolute risk, such as dia-
betic patients with well-controlled blood
pressure and average or below-average se-
rum cholesterol concentrations.
ASCOT (6) is a multicenter trial de-
signed to compare two antihypertensive
treatment strategies for the prevention of
coronary heart disease (CHD) events in
19,342 hypertensive patients who have
no history of CHD. In a two-by-two fac-
torial design, ASCOT included a double-
blind randomized comparison of the
cardiovascular effects of atorvastatin with
placebo among 10,305 patients who had
total cholesterol concentrations 6.5
mmol/l. The main results of the lipid-
lowering arm (LLA) of ASCOT have been
published (12). This report presents a de-
tailed analysis of the 2,532 diabetic par-
ticipants whose investigation was a
prespecified subsidiary aim of the trial.
RESEARCH DESIGN AND
METHODS— The study design, orga-
nization, measurements, end points, ra-
tionale, power calculations, recruitment
rates, and some baseline characteristics of
the ASCOT trial have been published pre-
viously (6). Patients eligible for inclusion
in ASCOT were men and women with hy-
pertension aged 40–79 years at random-
ization (6). Study participants were
required to have at least three of the fol-
lowing risk factors: type 2 diabetes, male
sex, age 55 years, microalbuminuria or
proteinuria, smoking, ratio of plasma to-
tal cholesterol to HDL cholesterol 6,
premature family history of CHD, left
ventricular hypertrophy, other specified
abnormalities on electrocardiogram, pe-
ripheral arterial disease, previous stroke,
or transient ischemic attack.
The diagnosis of type 2 diabetes was
based on a self-reported history and re-
ceiving any treatment including dietary
maneuvers, oral hypoglycemic agents, or
insulin. Further details are outlined on
the ASCOT web page (www.ascotstudy.
org). Patients who had not previously
been diagnosed as having type 2 diabetes
but who were found at baseline to have a
fasting glucose 6.0 mmol/l and a 2-h
value of 11.1mmol/l after a 75-g glu-
cose load were also considered as having
type 2 diabetes (13).
Exclusion criteria included previous
myocardial infarction, currently treated
angina, a cerebrovascular event within
the previous 3 months, fasting triglycer-
ide level 4.5 mmol/l, heart failure, un-
controlled arrhythmias, or any clinically
important hematological or biochemical
abnormality on routine screening. Eligi-
bility for ASCOT-LLA also required a total
cholesterol concentration 6.5 mmol/l
and no current use of a statin or fibrate.
Most patients in ASCOT-LLA were re-
cruited from family practice. The study
conformed to good clinical practice
guidelines and was undertaken following
the guidelines of the Declaration of Hel-
sinki. The protocol and all subsequent
amendments were reviewed and ratified
by ethics review boards in the U.K., Ire-
land, and the Nordic countries.
Patients were recruited between Feb-
ruary 1998 and May 2000. Eligibility cri-
teria were established and written
informed consent was obtained4 weeks
before randomization. Blood pressure
was measured using standard procedures;
nonfasting blood samples were collected
and 12-lead electrocardiograms were as-
sessed centrally. After the 4-week run-in
period, eligible recruits were randomized,
and they underwent a physical examina-
tion; blood pressure, heart rate, and 12-
lead electrocardiogram were again
recorded. Fasting blood samples were ob-
tained for total cholesterol, HDL choles-
terol, triglyceride, and glucose levels.
Patients with a nonfasting total cho-
lesterol concentration6.5 mmol/l at the
initial screening visit, who were untreated
with a statin or fibrate, were randomly
assigned by computer (using minimiza-
tion procedures) to receive atorvastatin
10 mg daily or matching placebo. Man-
agement of the blood pressure–lowering
arm is detailed elsewhere (6). Patients
were randomly assigned one of two anti-
hypertensive regimens. At each follow-up
visit, antihypertensive drug therapy was
titrated to achieve target blood pressures
(140/90 mmHg for nondiabetic pa-
tients and 130/80 mmHg for diabetic
patients); information was recorded
about adverse events and any new cardio-
vascular event or procedure, including
the cause for any hospital admission. In-
formation on potential end points was re-
viewed by a blinded end point committee.
Statistical methods
Given the observed rate of total cardiovas-
cular events and procedures among dia-
betic subjects in the placebo arm, a
median 3.3-year follow-up, and a two-
sided significance level of 5%, the study
had 75% power to detect a reduction of
25% in total cardiovascular events and
procedures among the 2,532 diabetic pa-
tients. Total cardiovascular events and
procedures included the following diag-
noses: cardiovascular mortality, nonfatal
myocardial infarction (symptomatic plus
silent), unstable angina, chronic stable
angina, life-threatening arrhythmias,
nonfatal heart failure, nonfatal stroke, pe-
ripheral arterial disease, retinal vascular
thrombosis, revascularization proce-
dures, transient ischemic attacks, and re-
versible ischemic neurological deficits.
We compared the times to first end
points in the atorvastatin and placebo
groups on an intention-to-treat basis. For
the main analyses, we used log-rank pro-
cedures and Cox’s proportional hazards
model to calculate confidence intervals.
Cumulative incidence curves were gener-
ated by the Kaplan-Meier method for all
cardiovascular events and procedures in
the active and placebo groups. ASCOT-
LLA was stopped prematurely after a me-
dian follow-up of 3.3 years on the
grounds that atorvastatin had resulted in a
highly significant reduction in the pri-
mary end point of fatal CHD events and
nonfatal myocardial infarction.
Role of the funding source
ASCOT was conceived, designed, and co-
ordinated by an independent investiga-
tor-led steering committee. The principal
ASCOT lipid-lowering arm
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funding source had two nonvoting mem-
bers on that committee. The trial database
is held independently and this report was
prepared independently of the principal
funding source.
RESULTS— In ASCOT, 19,342 pa-
tients were randomly assigned to one of
two antihypertensive regimens. In
ASCOT-LLA, 10,305 patients were fur-
ther randomly assigned atorvastatin 10
mg daily or placebo, of whom 2,532 were
classified as having type 2 diabetes. Base-
line characteristics of participants in these
two randomized groups were well
matched (Table 1). Overall, 90% of dia-
betic participants were white and 76%
male, with a mean age of 64 years. The
average number of additional risk factors
in the diabetic subpopulation was three.
Baseline blood pressures and lipid con-
centrations were almost identical in the
two groups. At the end of follow-up of the
LLA, complete information was obtained
for all except 30 of the diabetic patients
originally randomized; vital status was
obtained for all but four patients.
Among diabetic participants in the
atorvastatin group, total cholesterol and
calculated LDL cholesterol levels at year 1
of follow-up were lower than in the pla-
cebo group by 1.3 and 1.2 mmol/l, re-
spectively (Table 2). By the end of the
study, these differences were 0.9 and 0.9
mmol/l, respectively. In those allocated
atorvastatin compared with placebo, tri-
glyceride levels were lowered by 0.3
mmol/l after 1 year and 0.2 mmol/l at
study completion. Changes in HDL cho-
lesterol concentration were minimal in
both groups. After 3 years follow-up, 84%
of diabetic patients originally assigned
atorvastatin were still taking the statin
and 14% of those in the placebo group
had been prescribed open-label statins.
Blood pressure control throughout
the trial was similar in diabetic patients
assigned atorvastatin and placebo, with
mean values at the end of follow-up of
138.5 mmHg systolic and 77.7 mmHg dia-
stolic and 138.4 mmHg systolic and 77.3
mmHg diastolic, respectively. Body weight,
fasting blood glucose, and creatinine were
well matched at baseline and were unal-
tered in either group by the time of close
out. At randomization, 52% of the diabetic
patients were receiving oral hypoglycemic
drugs, and 7% were receiving insulin. By
the end of the trial, these proportions had
increased to 68 and 14%, respectively.
Compared with placebo, atorvastatin
significantly lowered the incidence of total
cardiovascular events and procedures
among the diabetic group by 23% (hazard
ratio [HR] 0.77, 95% CI 0.61–0.98; P 
0.036) (Fig. 1). This was similar to the pro-
portional reduction observed among partic-
ipants without diabetes (Fig. 2). Even
excluding 306 diabetic people with some
other preexisting cardiovascular disease,
there was still a significant reduction in total
cardiovascular events and procedures of
25% (95% CI 0.57– 0.99; P  0.038)
among the remaining 2,226 diabetic pa-
tients. A post hoc subgroup analysis of the
diabetic patients is shown in Table 3. Small
numbers of events in each subgroup limit
the validity of statistical comparisons. How-
ever, there is no statistical heterogeneity
within this population.
The effect of atorvastatin on total car-
diovascular events and procedures in the
diabetic subgroup was unaffected by
baseline cholesterol concentration. The
HRs were 0.72 (95% CI 0.44–1.18), 0.74
(0.52–1.05), and 0.84 (0.54–1.31) for
those with baseline cholesterol concen-
trations of 5.0, 5.0 to 6.0, and 6.0
mmol/l, respectively.
In the diabetic subgroup there were
no statistically significant effects of alloca-
tion to atorvastatin for any of the individ-
Table 1—Baseline characteristics for patients with diabetes in ASCOT-LLA
Atorvastatin Placebo
n 1,258 1,274
Demographics and clinical characteristics
Female sex 289 (23.0) 311 (24.4)
Age (years)
60 425 (33.8) 391 (30.7)
60 833 (66.2) 883 (69.3)
Means  SD 63.6  8.5 64.0  8.2
White 1,131 (89.9) 1,163 (91.3)
Current smoker 257 (20.4) 258 (20.3)
Alcohol consumption (units/week) 6.7  10.3 6.6  10.8)
Systolic blood pressure (mmHg) 165.1  17.6 164.8  17.1
Diastolic blood pressure (mmHg) 92.9  10.3 92.4  10.3
Heart rate (bpm) 73.7  13.2 74.1  13.1
BMI (kg/m2) 30.3  5.0 30.1  4.7
Total cholesterol (mmol/l) 5.3  0.8 5.3  0.8
LDL cholesterol (mmol/l) 3.3  0.7 3.3  0.8
HDL cholesterol (mmol/l) 1.2  0.3 1.2  0.3
Triglycerides (mmol/l) 1.9  1.0 1.9  1.0
Glucose (mmol/l) 8.6  2.8 8.7  2.8
Creatinine (mmol/l) 97.1  15.4 98.7  18.0
Medical history
Previous stroke /transient ischemic attack 93 (7.4) 98 (7.7)
LVH (according to ECG or ECHO) 119 (9.5) 111 (8.7)
ECG abnormalities other than LVH 180 (14.3) 194 (15.2)
Peripheral vascular disease 70 (5.6) 65 (5.1)
Other significant cardiovascular disease 50 (4.0) 43 (3.4)
Number of risk factors (including diabetes) 4.1  1.0 4.0  1.0
Drug therapy
Oral hypoglycemics 645 (51.3) 683 (53.6)
Insulin 92 (7.3) 96 (7.5)
Previous antihypertensive treatments
None 189 (15.0) 209 (16.4)
One 557 (44.3) 555 (43.6)
Two or more 512 (40.7) 510 (40.0)
Lipid-lowering therapy 14 (1.1) 20 (1.6)
Aspirin use 228 (18.1) 208 (16.3)
Data are n (%) or means  SD. ECG, electrocardiogram; ECHO, echocardiogram; LVH, left ventricular
hypertrophy.
Sever and Associates
DIABETES CARE, VOLUME 28, NUMBER 5, MAY 2005 1153
ual components of the composite end
point nor for any of the other predefined
secondary end points (Table 4). Numbers
of events for each component were small,
and estimates of hazard ratios were there-
fore necessarily unstable. However, risk
reductions in the primary end point of the
trial (fatal CHD and nonfatal myocardial
infarction) did not differ significantly be-
tween those with or without diabetes at
entry (16 and 44%, respectively; P 
0.14). Fatal and nonfatal strokes were
similarly reduced among those with or
without diabetes (33 and 24%, respec-
tively; P  0.66). The use of atorvastatin
in the diabetic population was not associ-
ated with any excess risk of adverse reac-
tions, and there were no significant
differences in liver enzyme abnormalities
between those allocated statin and pla-
cebo. No cases of rhabdomyolysis were
reported.
CONCLUSIONS— The risk reduc-
tions in cardiovascular events and proce-
dures reported here are similar for those
patients with and without diabetes. How-
ever, given that diabetic patients are at
higher absolute risk of a cardiovascular
event than those without diabetes (39 vs.
28 per 1,000 patient years, respectively,
in the placebo group), the absolute bene-
fit of this lipid-lowering therapy is greater
for those hypertensive patients who were
also diabetic. These benefits are over and
above those likely to have accrued as a
result of the extensive blood pressure
lowering achieved in ASCOT-LLA (12),
which previous trials (14,15) have clearly
shown to be associated with major reduc-
tions in cardiovascular events in the dia-
betic population.
These risk reductions in the diabetic
population in ASCOT-LLA were associ-
ated with an average reduction in total
and LDL cholesterol concentrations of
1 mmol/l. These differences in choles-
terol between active and placebo groups
were somewhat less at the close of the trial
than at the end of the first year because
14% of the patients with diabetes who
were originally allocated placebo treat-
ment were subsequently prescribed
open-label statins by practitioners, com-
pared with 8% for the nondiabetic popu-
lation in ASCOT-LLA.
In the total ASCOT-LLA population,
the primary end point of nonfatal myocar-
dial infarction and fatal CHD was reduced
by 36% (P 0.0005). Among the diabetic
subgroup, the observed 16% risk reduc-
tion was not statistically significant, but
only 84 such first events occurred among
these diabetic participants; the propor-
tional reduction was not significantly dif-
ferent from the reduction among the
nondiabetic participants. The premature
stopping of the trial reduced the antici-
pated number of coronary events and
other end points, and hence the power of
any tests to compare effects of statin with
placebo in the subgroups.
Figure 1—Cumulative incidence for total cardiovascular events and procedures among diabetic
participants in ASCOT-LLA.T
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Three other studies have recently re-
ported observations on statin use in dia-
betic patients. Among 5,963 diabetic
participants in the HPS (10), allocation to
simvastatin resulted in an average reduc-
tion in LDL cholesterol concentration of
1.0 mmol/l and reduced the incidence of
major vascular events by 24%, which is a
risk reduction similar to that reported in
this article. Lipid profiles in diabetic pa-
tients in HPS showed some important dif-
ferences from those in ASCOT-LLA. In
HPS, diabetic participants had higher to-
tal cholesterol levels (5.7 vs. 5.3 mmol/l)
and lower HDL cholesterol levels (1.1 vs.
1.2 mmol/l) than those in ASCOT-LLA.
Additionally, the diabetic subgroup in the
HPS was at substantially higher absolute
cardiovascular risk because of much
higher rates of preexisting cardiovascular
disease. However, even in the subgroup of
2,912 HPS diabetic patients without
known cardiovascular disease, similar
and significant risk reductions in cardio-
vascular end points were reported (10).
In the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart At-
tack Tr ia l–L ip id Lower ing Tr ia l
(ALLHAT-LLT) (16), 3,638 hypertensive
patients with diabetes were randomly as-
signed to pravastatin (40 mg daily) or
“usual care,” and followed for an average
of 5.2 years. Overall, the ALLHAT-LLT
population was older and at higher cardio-
vascular risk than the ASCOT-LLA partici-
pants. Among the diabetic population in
ALLHAT-LLT, the use of pravastatin was as-
sociated with an 11% nonsignificant reduc-
tion in fatal CHD and nonfatal myocardial
infarction. However, these data are difficult
to interpret because in the whole ALLHAT-
LLT population, the differential effect of
pravastatin on total and LDL cholesterol (11
and 17%, respectively) was smaller than ex-
pected due to extensive statin use in the
usual care group. This contrasts with equiv-
alent figures of 24 and 35%, respectively, in
the whole ASCOT-LLA population.
In CARDS (11), the reduction in the
composite end point of major cardiovas-
cular events for the same dose of atorva-
statin was greater than that reported
here for total cardiovascular events and
procedures among diabetic subjects in
ASCOT-LLA (37 vs. 23%). However, the
composition of these two end points is
different and so the data are not strictly
comparable (6,11). Nevertheless, fatal
CHD and nonfatal myocardial infarctions
were reduced by 33% in CARDS (HR
0.67, 95% CI 0.47–0.97) and only by
16% in ASCOT-LLA (0.84, 0.55–1.29).
The percentage reduction in stroke ob-
Figure 2—Effect of atorvastatin and
placebo on cardiovascular (CV) and
coronary end points by diabetic status
in ASCOT-LLA.MI, myocardial infarc-
tion. *Per 1,000 patient-years.
Table 3—HR by subgroups (diabetic patients only) for total cardiovascular events and procedures
Atorvastatin Placebo
Unadjusted HR (95% CI) P valuen (%) Rate* n (%) Rate*
Age 60 years 20 (4.7) 14.9 34 (8.7) 28 0.53 (0.31–0.92) 0.022
Age 60 years 96 (11.5) 38.4 117 (13.3) 44.3 0.87 (0.66–1.14) 0.300
Female sex 26 (9.0) 28.8 31 (10.0) 31.9 0.90 (0.53–1.51) 0.686
Male sex 90 (9.3) 30.6 120 (12.5) 41.6 0.74 (0.56–0.97 0.028
LDL 3.46 mmol/l 56 (8.5) 27.5 62 (9.1) 29.3 0.93 (0.65–1.34) 0.708
LDL 3.46 mmol/l 53 (10.8) 36.3 72 (15.5) 52.9 0.69 (0.48–0.98) 0.037
HDL 1.3 mmol/l 67 (9.2) 30.6 96 (12.7) 42.7 0.72 (0.52–0.98) 0.036
HDL 1.3 mmol/l 49 (9.3) 29.7 55 (10.6) 34.1 0.87 (0.59–1.28) 0.481
Triglycerides 1.4 mmol/l 37 (8.7) 28.2 55 (13.3) 43.8 0.64 (0.42–0.97) 0.036
Triglycerides 1.4 mmol/l 72 (9.5) 31.6 81 (10.6) 35.1 0.90 (0.65–1.24) 0.512
Glucose 5.6 mmol/l 5 (6.0) 19.4 8 (10.1) 33.1 0.59 (0.19–1.81) 0.354
Glucose 5.6 mmol/l 104 (9.5) 31.2 128 (11.7) 38.6 0.81 (0.62–1.05) 0.105
All diabetic patients 116 (9.2) 30.2 151 (11.9) 39.1 0.77 (0.61–0.98) 0.036
*Rates are per 1,000 patient-years.
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served in the CARDS trial of 48% (0.52,
0.31–0.89) was larger than the 33% re-
duction seen in ASCOT-LLA (0.67, 0.41–
1.09). The latter reduction is larger than
observed in most previous statin trials, in-
cluding the 24% reduction experienced
among the diabetic population in HPS
(10). These apparent disparities may be
the result of chance (e.g., only 84 and 108
fatal CHD and nonfatal myocardial infarc-
tion events occurred in ASCOT-LLA and
CARDS, respectively). In addition, the
greater impact of atorvastatin on LDL
cholesterol and triglyceride levels relative
to placebo seen in CARDS (at least in part
reflecting more drop-in and drop-out to/
from therapy in ASCOT-LLA), may have
contributed to the greater impact seen in
CARDS.
It is also possible that other factors
could have influenced the benefits of ator-
vastatin in ASCOT-LLA. For example,
-blockers and diuretics that were allo-
cated to 50% of ASCOT-LLA patients may
have adversely affected lipid profiles more
among those taking a statin than placebo
and thereby have reduced the relative
benefits of statins.
Thus, findings among the large sub-
group of patients with type 2 diabetes in
the ASCOT-LLA support those arising
from analyses of the diabetic subgroups of
earlier statin trials (10,17) and from
CARDS (11). These data also extend the
database specifically in relation to pa-
tients with hypertension and no history of
CHD. Hence the findings reinforce recent
guidelines that advocate a more aggres-
sive approach to lipid-lowering therapy
for patients with diabetes (18–20). It now
therefore seems reasonable to recom-
mend that all patients with type 2 diabetes
and hypertension (at least all those 50
years of age and/or having diabetes for
10 years) should be routinely consid-
ered for statin therapy.
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